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or the Prediction of Incident Heart Failure and Atrial Fibrillation
Objectives The purpose of this study was to assess the predictive accuracy of conventional cardiovascular risk factors for
incident heart failure and atrial fibrillation, and the added benefit of multiple biomarkers reflecting diverse
pathophysiological pathways.
Background Heart failure and atrial fibrillation are interrelated cardiac diseases associated with substantial morbidity and
mortality and increasing incidence. Data on prediction and prevention of these diseases in healthy individuals
are limited.
Methods In 5,187 individuals from the community-based MDCS (Malmö Diet and Cancer Study), we studied the perfor-
mance of conventional risk factors and 6 biomarkers including midregional pro-atrial natriuretic peptide (MR-
proANP), N-terminal pro–B-type natriuretic peptide (NT-proBNP), midregional pro-adrenomedullin, cystatin C,
C-reactive protein (CRP), and copeptin.
Results During a mean follow-up of 14 years, 112 individuals were diagnosed with heart failure and 284 individuals with
atrial fibrillation. NT-proBNP (hazard ratio [HR]: 1.63 per SD, 95% confidence interval [CI]: 1.29 to 2.06, p 
0.001), CRP (HR: 1.57 per SD, 95% CI: 1.28 to 1.94, p  0.001), and MR-proANP (HR: 1.26 per SD, 95% CI:
1.02 to 1.56, p  0.03) predicted incident heart failure independently of conventional risk factors and other bi-
omarkers. MR-proANP (HR: 1.62, 95% CI: 1.42 to 1.84, p  0.001) and CRP (HR: 1.18, 95% CI: 1.03 to 1.34,
p  0.01) independently predicted atrial fibrillation. Addition of biomarkers to conventional risk factors im-
proved c-statistics from 0.815 to 0.842 for heart failure and from 0.732 to 0.753 for atrial fibrillation and the
integrated discrimination improvement for both diseases (p  0.001). Net reclassification improvement (NRI)
with biomarkers was observed in 22% of individuals for heart failure (NRI, p  0.001) and in 7% for atrial fibril-
lation (NRI, p  0.06), mainly due to up-classification of individuals who developed disease (heart failure: 29%,
atrial fibrillation: 19%). Addition of CRP to natriuretic peptides did not improve discrimination or reclassification.
Conclusions Conventional cardiovascular risk factors predict incident heart failure and atrial fibrillation with reasonable accu-
racy in middle-age individuals free from disease. Natriuretic peptides, but not other biomarkers, improve discrim-
ination modestly for both diseases above and beyond conventional risk factors and substantially improve risk
classification for heart failure. (J Am Coll Cardiol 2010;56:1712–9) © 2010 by the American College of
Cardiology Foundations
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ulthough the incidence of coronary heart disease has
eclined in recent years, the incidence of heart failure and
trial fibrillation has risen (1). These interrelated diseases
2) are major causes of morbidity and mortality (3,4), with
ifetime risks as high as 20% and 25%, respectively (5,6).
ccordingly, practice guidelines for heart failure and atrial
brillation have shifted their emphasis from treatment to
revention (7,8).
The identification of individuals at risk for heart failure
nd atrial fibrillation remains a challenge, however. Previous
ontinuing Medical Education (CME) is available for this article. From the
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ermany. The Malmö Diet and Cancer study was made possible by grants from the
almö city council. Biomarker measurements were performed and funded by
RAHMS AG and Siemens Diagnostics. Drs. Smith, Platonov, Hedblad, Engström,
nd Melander were supported by the Swedish Heart-Lung Foundation. Dr. Newton-
heh was supported by National Institutes of Health (NIH) grant K23-HL-080025,
Doris Duke Charitable Foundation Clinical Scientist Development Award, a
urroughs Wellcome Fund Career Award for Medical Scientists, and served on the atudies have identified risk factors for heart failure (9,10)
nd atrial fibrillation (11,12), and risk scores for risk
ssessment have been developed (13–15). However, these
cores have focused on specific subgroups (elderly, patients
ith hypertension, coronary heart disease, or valvular heart
isease) and require information on markers rarely used in
he clinic today, such as radiologic evidence of cardiomeg-
ly. Additionally, many individuals who develop heart
ailure and atrial fibrillation are not identified by risk factors,
eflecting the etiologic heterogeneity of these diseases.
dvisory board for Merck. Dr. Platonov was supported by the governmental funding
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Prediction of Heart Failure and Atrial Fibrillation November 16, 2010:1712–9Asymptomatic ventricular dysfunc-
tion frequently precedes heart failure
or atrial fibrillation, but routine
screening echocardiography is pro-
hibitively expensive and not cur-
rently recommended in the general
population. It has been suggested
that biomarkers reflecting com-
mon pathophysiological processes
(16) may perform better than stan-
dard risk factors and identify indi-
viduals who might benefit from
echocardiographic screening. A
number of plasma biomarkers have
been related to heart failure (16)
and atrial fibrillation risk (17,18).
However, the predictive value of
models incorporating multiple bi-
omarkers together has not been
well established.
In a population-based sample of middle-aged individuals,
e sought to evaluate the predictive accuracy of conven-
ional cardiovascular risk factors and the incremental pre-
ictive value of a panel of biomarkers reflecting diverse
athophysiological pathways implicated in heart failure and
trial fibrillation including hemodynamic stress (the midre-
ional fragment of pro-atrial natriuretic peptides [MR-
roANP], the amino-terminal fragment of pro–B-type
atriuretic peptide [NT-proBNP], the midregional frag-
ent of pro-adrenomedullin [MR-proADM]), plasma vol-
me and osmolarity (copeptin), inflammation (C-reactive
rotein [CRP]), and renal function (cystatin C). We evalu-
ted model improvement using both the c-statistic and the
ewer measures of integrated discrimination improvement
IDI) and net reclassification improvement (NRI) (19–21).
ethods
tudy sample. The MDCS (Malmö Diet and Cancer
tudy) is a prospective cohort study that includes 28,449
en (born between 1923 and 1945) and women (born
etween 1923 and 1950) from the city of Malmö in
outhern Sweden who underwent baseline examinations
etween 1991 and 1996. From this cohort, 6,103 individuals
ith a baseline examination between 1991 and 1994 were
andomly selected to participate in a study of cardiovascular
isk factors, the MDCS Cardiovascular Cohort (MDC-
C), of whom 5,543 underwent blood sampling under
tandardized fasting conditions (22). Information on all
onventional risk factors was available in 5,187 individuals,
hich constitutes the sample examined in the current study.
lood pressure (systolic and diastolic) was measured using a
ercury-column sphygmomanometer after 10 min of rest in
he supine position. Data on current smoking, diabetes
ellitus, and use of antihypertensive and antidiabetic med-
Abbreviations
and Acronyms
CRP  C-reactive protein
ICD  International
Classification of Diseases
IDI  integrated
discrimination improvement
MR-proADM  midregional
pro-adrenomedullin
MR-proANP  midregional
pro-atrial natriuretic
peptide
NRI  net reclassification
improvement
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
ROC  receiver-operating
characteristiccations was ascertained from a questionnaire. Diabetes oellitus was defined as fasting blood glucose 6.0 mmol/l,
elf-reported physician diagnosis, or use of antidiabetic
edications. MDCS was approved by the Ethics Commit-
ee of Lund University, Sweden, and all individuals pro-
ided informed consent.
scertainment of end points. Cardiac disease end points
ere ascertained by linkage of Swedish personal identifica-
ion numbers to the national Swedish registers (Swedish
ospital Discharge Register, Swedish Cause of Death
egister) maintained by the Swedish National Board of
ealth and Welfare. High case validity in these registers has
een previously found for heart failure (23), myocardial
nfarction (24), and atrial fibrillation (25). Heart failure was
scertained from the Swedish Hospital Discharge Register
sing diagnosis codes 427.00, 427.10, and 428.99 for
nternational Classification of Diseases-8th Revision (ICD-8),
28 for the 9th Revision (ICD-9), and I50 and I11.0 for the
0th Revision (ICD-10) as primary diagnosis as in previous
tudies (23). Atrial fibrillation was defined using diagnosis
odes 427.92 (ICD-8), 427D (ICD-9), and I48 (ICD-10)
s in previous studies (25). Myocardial infarction was
efined using diagnosis codes 410 (ICD-8 and -9) and I21
ICD-10) or as death from ischemic heart disease defined
sing diagnosis codes 412 and 414 (ICD-8 and -9) or
22-I23 and I25 (ICD-10) as in previous studies (24).
ollow-up extended to January 1, 2007.
aboratory measurements. Measurements of fasting
lood glucose, HbA1c, insulin, and cholesterol (HDL,
riglycerides, total cholesterol) levels were performed in
DC-CC on fresh blood samples according to standard
rocedures at the Department of Clinical Chemistry, Uni-
ersity Hospital Malmö, as described previously (22).
lasma biomarkers were measured from fasting plasma
amples that had been frozen at 80°C immediately after
ollection and that had not previously been thawed (22).
opeptin and the midregional fragments of pro-atrial na-
riuretic peptide and pro-adrenomedullin were measured
sing immunoluminometric sandwich assays (BRAHMS,
erlin, Germany). NT-proBNP was measured using the
utomated Dimension Vista Intelligent Lab System method
Siemens Healthcare Diagnostics Inc., Deerfield, Illinois).
RP was measured by a high-sensitivity assay (Roche Diag-
ostics, Basel, Switzerland). Cystatin C was measured using a
article-enhanced immuno-nephelometric assay (N Latex
ystatin, Siemens Diagnostics).
tatistical analysis. One individual whose personal identi-
cation number did not match national registers was ex-
luded from all analyses, and individuals with prevalent
trial fibrillation or prevalent heart failure were excluded
rom analyses of the respective disease. MR-proANP, NT-
roBNP, CRP, and copeptin showed right-skewed distri-
utions and underwent natural logarithmic transformation.
ll biomarkers were scaled to an SD of 1 for ease of
omparison. Cox proportional hazards models were used to
ssess association of biomarkers with disease independently
f conventional risk factors, with Wald tests for biomarker
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November 16, 2010:1712–9 Prediction of Heart Failure and Atrial Fibrillationignificance testing. The proportionality of hazards assump-
ion was confirmed using Schoenfeld’s global test. We first
ssessed association between each disease and each biomar-
er after adjustment for conventional risk factors. All
iomarkers associated with disease (p  0.05) were then
ncluded in a backward elimination model with adjustment
or conventional risk factors. Performance of the final
odels was evaluated using the c-statistic, a generalization
f the area under the receiver-operating characteristic
ROC) curve. Adequate calibration of all final models across
uantiles was confirmed using the Grønnesby and Borgan
est (26). We tested models for the IDI and for reclassifi-
ation of individuals into risk categories as the NRI, the
roportion of individuals correctly reclassified across risk
ategories minus the proportion of individuals incorrectly
eclassified (20). Finally, we created multimarker risk scores
y summing individual z-scores weighted by the beta
stimate per SD for each biomarker. Kaplan-Meier curves
f cumulative incidence were created for comparison of
ultimarker score quartiles.
The conventional models were determined using regres-
ion analysis with backward elimination including age, sex,
ystolic blood pressure, diastolic blood pressure, use of
ntihypertensive treatment, body mass index, low-density
ipoprotein, high-density lipoprotein, current smoking, his-
ory of diabetes mellitus, and history of myocardial infarc-
ion. A history of heart failure was also included for atrial
brillation. For heart failure, we used risk category thresholds
f 6%, 6% to 20%, and 20% that have been used for
oronary heart disease (22,27). For atrial fibrillation, we used
isk category thresholds of 5%, 5% to 15%, and 15% as
roposed for the Framingham prediction model (14).
Secondary analyses were performed with censoring at
ncident myocardial infarction for heart failure and with
ensoring at incident myocardial infarction or heart failure
or atrial fibrillation. Two-sided p values 0.05 were
onsidered significant. All analyses were performed in SPSS
ersion 16 (SPSS Inc., Chicago, Illinois) or STATA version 8
StataCorp, College Station, Texas).
esults
aseline characteristics are shown in Table 1. Atrial fibril-
ation was prevalent in 47 individuals (0.9%) and heart
ailure in 8 individuals (0.2%). During a median follow-up
f 13.8 years, 112 individuals were diagnosed with new-
nset heart failure and 284 individuals were diagnosed with
ew-onset atrial fibrillation. Of the 63 individuals (1.2%)
ith both conditions at the end of follow-up, 39 (62%) were
iagnosed with atrial fibrillation before heart failure, 15
24%) were diagnosed with heart failure before atrial fibril-
ation, and 9 (14%) received both diagnoses on the same
ay.
rediction of heart failure and atrial fibrillation with
onventional risk factors. Independently significant con-
entional risk factors used in final models are shown in pable 2 with corresponding hazard ratios. The c-statistic of
onventional risk factors was 0.815 for heart failure and
.732 for atrial fibrillation as shown in Table 3.
iomarkers for prediction of incident heart failure. All
iomarkers when considered individually were significantly
ssociated with heart failure after adjustment for conven-
ional risk factors as shown in Table 2. In multivariable
egression models with backward elimination including all
ignificant biomarkers and conventional risk factors, NT-
roBNP, MR-proANP, and CRP remained significant
redictors of heart failure as also shown in Table 2. In
econdary analyses with censoring at incident myocardial
nfarction, NT-proBNP and CRP, but not MR-proANP,
emained significant predictors. The pairwise correlation of
iomarkers is shown in Online Table 1.
iomarkers for prediction of incident atrial fibrillation.
R-proANP, NT-proBNP, MR-proADM, and CRP
ere associated with atrial fibrillation after adjustment for
onventional risk factors as shown in Table 2. In multiva-
iable regression models with backward elimination includ-
ng all significant biomarkers and conventional risk factors,
R-proANP and CRP remained significant as also shown
n Table 2. In a secondary analysis with censoring at
yocardial infarction or heart failure, both MR-proANP
nd CRP remained significant predictors independently of
onventional risk factors.
iomarkers and disease discrimination. For heart failure,
mprovement in discrimination compared with the model
ith conventional risk factors was observed with inclusion
ndividually of NT-proBNP (c-statistic  0.837), MR-
aseline CharacteristicsTable 1 Baseline Characteristics
Age, yrs 57.6 5.9
Male 2,094 (41)
Systolic blood pressure, mm Hg 141.4 19.0
Diastolic blood pressure, mm Hg 86.9 9.4
Antihypertensive treatment 850 (17)
Body mass index, kg/m2 25.7 3.9
Low-density lipoprotein, mmol/l 4.2 1.0
High-density lipoprotein, mmol/l 1.4 0.4
Diabetes mellitus 399 (8)
Current smoking 1,379 (27)
History of myocardial infarction 75 (2)
Midregional pro-atrial natriuretic peptide, pmol/l
(n  4,880)
66.1 (50.9–85.9)
N-terminal pro–B-type natriuretic peptide, pg/ml
(n  4,778)
61.0 (34.0–111.0)
Midregional pro-adrenomedullin, nmol/l (n  4,879) 0.5 0.1
C-reactive protein, mg/l (n  4,922) 1.4 (0.7–2.8)
Cystatin C, mg/l (n  4,777) 0.8 0.1
Copeptin, pmol/l (n  4,873) 5.1 (3.2–8.1)
hown are baseline characteristics of 5,135 individuals free of atrial fibrillation and heart failure at
aseline and with information on all conventional risk factors. For continuous traits, mean SD are
iven for normally distributed traits, and median (interquartile range) for right skewed traits. For
ategorical traits, n (%) are given.roANP (c-statistic  0.824), or CRP (c-statistic  0.823)
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Prediction of Heart Failure and Atrial Fibrillation November 16, 2010:1712–9n the model as shown in Table 3. Inclusion of all 3 markers
ogether resulted in a c-statistic of 0.842.
For atrial fibrillation, improvement in discrimination
ompared with the model with conventional risk factors was
bserved with inclusion of MR-proANP (c-statistic 
.750) in the model and, minimally, with CRP (c-statistic
.734). Inclusion of both biomarkers yielded a c-statistic of
.753.
iomarkers and risk category reclassification. Net reclas-
ification improvement was observed in 22% of individuals for
Conventional Risk Factors and Biomarkers for PTable 2 Conventional Risk Factors and Biom
HF Model 1
Age 1.12 (1.07–1.16) 1
Female sex 0.52 (0.35–0.77) 0
Body mass index 1.05 (1.00–1.10) 1
SBP —
DBP —
Antihypertensive treatment 2.40 (1.59–3.62) 1
LDL cholesterol —
History of MI 4.13 (2.29–7.44) 3
History of diabetes 2.82 (1.81–4.39) 2
Current smoking 1.71 (1.13–2.59) 1
lnMR-proANP 1.68 (1.41–2.00) 1
lnNT-proBNP 1.95 (1.63–2.34) 1
MR-proADM 1.35 (1.17–1.56)
lnCRP 1.67 (1.37–2.03) 1
CystC 1.20 (1.06–1.36)
lnCopeptin 1.35 (1.03–1.77)
Shown are hazards ratios for conventional risk factors and biomarkers
Results are shown for each end point for a model with only conventiona
factors (model 1) and models with all individually significant biomarke
(model 2).
AF  atrial fibrillation; BMI  body mass index; CRP  C-reactive
failure; LDL  low-density lipoprotein; ln  natural log transf
adrenomedullin; MR-proANP  midregional pro-atrial natriuretic pep
blood pressure.
iscrimination and Risk Categoryeclassification Using BiomarkersTable 3 Discrimination and Risk CategoryReclassification Using Biomarkers
c-Statistic IDI NRI
Heart failure
Conventional risk factors 0.815 — —
MR-proANP 0.824 0.03 (p 0.001) 14% (p 0.005)
NT-proBNP 0.837 0.03 (p 0.001) 16% (p 0.003)
CRP 0.823 0.01 (p 0.02) 7% (p 0.10)
MR-proANP, NT-proBNP 0.838 0.03 (p 0.001) 17% (p 0.002)
CRP, NT-proBNP 0.842 0.04 (p 0.001) 19% (p 0.003)
All biomarkers 0.842 0.05 (p 0.001) 22% (p 0.001)
Atrial fibrillation
Conventional risk factors 0.732 — —
MR-proANP 0.750 0.02 (p 0.001) 8% (p 0.04)
CRP 0.734 0.001 (p 0.25) 2% (p 0.32)
Both 0.753 0.02 (p 0.001) 7% (p 0.06)
hown are measures of discrimination and reclassification for models with conventional risk
actors only and models with the addition of biomarkers to conventional risk factors for heart
ailure (HF) and atrial fibrillation (AF). For IDI, the IDI statistics and p values are shown. For NRI, the
roportion of individuals correctly reclassified minus the proportion of individuals incorrectlya
eclassified and p values are shown.
Abbreviations as in Table 2.eart failure with the addition to conventional risk factors of all
biomarkers (CRP, MR-proANP, NT-proBNP; NRI p 
.001), mostly due to substantial upward reclassification to a
igher risk category (29%) of individuals who were subse-
uently diagnosed with heart failure during follow-up. For
trial fibrillation, 7% of individuals were reclassified by a model
ith both biomarkers (CRP, MR-proANP; NRI p  0.06),
ostly due to substantial upward reclassification (19%) of
ndividuals who were diagnosed with atrial fibrillation during
ollow-up to a higher risk category. Multimarker scores yielded
imilar results with 22% NRI (NRI p 0.001) for heart failure
nd 6% reclassification (NRI p  0.07) for atrial fibrillation.
esults for NRI are shown in Table 3, and numbers reclassified
re shown in Table 4. Significant improvement of IDI was also
bserved for both diseases (p  0.001). The cumulative
ncidence of heart failure and atrial fibrillation across quartiles
f the multimarker risk score is shown in Figure 1. When
dded to a model with NT-proBNP and conventional risk
actors, neither MR-proANP (p 0.94) nor CRP (p 0.61)
mproved NRI, but improved IDI (MR-proANP: 0.007, p 
.02; CRP: 0.01, p 0.005) for heart failure. The addition of
RP to MR-proANP and conventional risk factors did not
mprove classification (p  0.77) or IDI (p  0.43) for atrial
brillation.
iscussion
n this community-based cohort, we found that conven-
ional cardiovascular risk factors predicted heart failure and
trial fibrillation with reasonable accuracy and that the
tion of Incident HF and AFrs for Prediction of Incident HF and AF
odel 2 AF Model 1 AF Model 2
04–1.13) 1.11 (1.08–1.14) 1.09 (1.06–1.12)
31–0.75) 0.61 (0.48–0.78) 0.55 (0.42–0.70)
98–1.09) 1.05 (1.02–1.08) 1.05 (1.01–1.08)
1.01 (1.00–1.02) 1.01 (1.00–1.02)
0.98 (0.96–1.00) 0.99 (0.98–1.01)
20–3.04) 1.38 (1.04–1.84) 1.21 (0.89–1.64)
1.05 (1.02–1.08) 0.90 (0.78–1.02)
64–5.76) 2.64 (1.57–4.44) 1.81 (1.05–3.13)
82–4.70) — —
99–2.46) — —
02–1.56) 1.67 (1.47–1.89) 1.62 (1.42–1.84)
29–2.06) 1.45 (1.28–1.65) —
1.26 (1.12–1.41) —
28–1.94) 1.17 (1.04–1.33) 1.18 (1.03–1.34)
1.11 (1.00–1.24) —
1.09 (0.95–1.26) —
with 95% confidence intervals from Cox proportional hazards models.
ctors and for single biomarkers with adjustment for conventional risk
sted for traditional risk factors and backward elimination at p  0.05
n; CystC  cystatin C; DBP  diastolic blood pressure; HF  heart
MI  myocardial infarction; MR-proADM  midregional pro-
-proBNP  N-terminal pro–B-type natriuretic peptide; SBP  systolicredicarke
HF M
.09 (1.
.48 (0.
.03 (0.
—
—
.91 (1.
—
.07 (1.
.93 (1.
.56 (0.
.26 (1.
.63 (1.
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.57 (1.
—
—
per SD
l risk fa
rs adju
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ormed;ddition of biomarkers to conventional risk factors modestly
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November 16, 2010:1712–9 Prediction of Heart Failure and Atrial Fibrillationmproved discrimination for both diseases and substantially
mproved risk classification for heart failure. This improve-
ent was mainly mediated by natriuretic peptides. These
ndings stand in contrast to the weaker performance of
ontemporary cardiovascular biomarkers (such as CRP and
NP) in improving discrimination and risk category classi-
cation for atherosclerotic events above conventional risk
actors in the general population (22,28,29). One potential
xplanation for this difference could be a smaller value of
onventional risk factors for prediction of heart failure and
trial fibrillation, compared with atherosclerotic events,
roviding greater room for improvement with biomarkers.
ndeed, the population-attributable risk for conventional
isk factors for myocardial infarction (30) has been described
o be substantially higher than for heart failure (10,31) and
trial fibrillation (11). Still, we observed excellent discrim-
nation of heart failure using conventional risk factors
c-statistic  0.815) and acceptable discrimination of atrial
brillation (c-statistic  0.753). Our models with conven-
ional risk factors contained fewer risk factors and had
imilar or better predictive accuracy to that described for
revious models for both AF and HF (14,15).
indings and implications for HF. Prior studies have
oted the association of CRP and natriuretic peptides with
uture heart failure (16), but there has been limited infor-
ation regarding the additive value of these biomarkers for
isk prediction. Furthermore, prior studies have frequently
ncluded fewer than 100 heart failure events. Thus, the
resent investigation extends the findings of prior studies to
larger cohort, with the use of novel predictive indexes and
ssessment of a large panel of contemporary biomarkers.
Our data suggest that the association between NT-
isk Classification by Modelsith and Without Biomark r for HF or AFTable 4 Risk Classification by M delsWith and Without Biomarkers for HF or AF
Model With
Conventional
Risk Factors
Model With Biomarkers
Category 1 Category 2 Category 3 Total
Heart failure
Category 1
(6%)
44/4,274 14/108 3/7 61/4,389
Category 2
(6% to 20%)
5/124 9/124 11/30 25/278
Category 3
(20%)
0/0 2/12 8/25 10/37
Total 49/4,398 25/244 22/62 96/4,704
Atrial fibrillation
Category 1
(5%)
57/2,640 15/221 0/0 72/2,861
Category 2
(5% to 15%)
24/388 92/1,228 34/137 150/1,753
Category 3
(15%)
0/0 13/64 21/105 34/169
Total 81/3,028 120/1,513 55/242 256/4,783
eclassification across risk groups defined as6%, 6% to20%,20% for heart failure (HF) and
efined as5%, 5% to 15%,15% for atrial fibrillation (AF). Numbers in the cells refer to numbers
f observed events during follow-up over the total number of individuals in each combination of
ategories.roBNP, MR-proANP, and CRP with heart failure risks not mediated by interim myocardial infarction. Mild
atriuretic peptide elevation may reflect asymptomatic left
entricular systolic or diastolic dysfunction (32,33). Asymp-
omatic left ventricular dysfunction is common in the
opulation (32), and can progress to heart failure over time
34,35). Although we did not have concurrent echocardio-
raphic measures, it is interesting to note that prior inves-
igations have found the association of BNP with incident
eart failure to be independent of left ventricular mass,
jection fraction, or left atrial enlargement, suggesting that
atriuretic peptide elevations may reflect more subtle cardiac
bnormalities. The association of CRP with heart failure
as been postulated to reflect active inflammatory processes
n the myocardium which, following an initial precipitating
Figure 1 Cumulative Incidence of HF and AF
Panels show the cumulative incidence of (A) heart failure (HF) and (B) atrial
fibrillation (AF) during follow-up across quartiles of multimarker scores. Individu-
als in A were free of HF at baseline, and individuals in B were free of AF at
baseline. Risk score distribution expressed as median (minimum, maximum)
for HF was 3.4 (11.2, 2.0) for the first quartile (Q1), 1.0 (2.0, 0.6)
for the second quartile (Q2), 0.8 (0.6, 1.9) for the third quartile (Q3), and
3.3 (1.9, 13.2) for the fourth quartile (Q4). Risk score distribution for AF was
2.2 (12.7, 1.3) for the first quartile, 0.7 (1.3, 0.3) for the second
quartile, 0.5 (0.3, 1.2) for the third quartile, and 2.2 (1.2, 11.2) for the
fourth quartile. p values for trend were 0.001 for both HF and AF.
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hambers (16,18). However, further data are warranted to
stablish the underlying mechanisms, and the improvement
n discrimination with CRP was modest. It is possible that
etter markers reflecting myocardial remodeling and other
athways exist and will improve risk prediction beyond
atriuretic peptides.
Improved ability to identify individuals at risk for heart
ailure could be useful to identify individuals who might
enefit from echocardiographic testing and to guide preven-
ive interventions such as angiotensin-converting enzyme
nhibitors, which have been found to prevent the develop-
ent of heart failure and improve survival in individuals
ith asymptomatic left ventricular dysfunction (34,36).
urther studies are necessary to determine whether any
ubgroups might benefit more from biomarker testing, what
he appropriate follow-up of positive biomarker results
hould be (e.g., echocardiography), and the cost effective-
ess of more widespread screening (37,38).
indings and implications for atrial fibrillation. Natri-
retic peptides and inflammation were also the best markers
or atrial fibrillation. Our data suggest that these associa-
ions are not mediated by interim myocardial infarction and
eart failure. Interestingly, MR-proANP performed slightly
etter than NT-proBNP, suggesting that the former could
e a better marker of the atrial stress leading to atrial
brillation. This finding is supported by the observation in
he Framingham Heart Study that N-terminal pro-atrial
atriuretic peptide levels predicted atrial fibrillation more
trongly than NT-proBNP (17). CRP predicted atrial
brillation with similar risk estimates as in a previous study
18). However, CRP, a relatively weak predictor on its own
ith only minimal improvement in discrimination, did not
ubstantially improve prediction when added to MR-
roANP.
Unfortunately, no preventive treatments for atrial fibril-
ation have been established. Subgroup analyses of clinical
rials have shown interesting results with angiotensin recep-
or inhibitors, statins, and beta-blockers, and calls for
dditional trials to address this issue have been raised, but
he current data are inconclusive (8).
tudy strengths and limitations. We used a large sample
ith long follow-up, enabling identification of large num-
ers of disease events. Our use of national register data
ould potentially reduce the impact of attendance bias on
nd point ascertainment, which could be substantial for
eart failure. High case validity of atrial fibrillation, heart
ailure, and myocardial infarction has been validated in these
egisters (23–25). However, as disease outcomes were as-
ertained from national registers on cause of death and
ospitalization, it is possible that individuals who developed
isease but were not hospitalized escaped detection, leading
o underestimates of disease rates. It seems less likely that
hese effects would be differential based on the biomarkers
easured here and thus would be more likely to bias ourtudy to the null.onclusions
ur findings provide evidence that natriuretic peptides
mprove prediction of incident heart failure and atrial
brillation in the general population in addition to conven-
ional risk factors. Whether individuals with elevated levels
f these biomarkers will benefit from further testing and
reventive therapy remains to be determined.
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